Macquarie Group’s Evoke Pharma EVOK Stock Holding History

Macquarie Group’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-99	Closed	-$32K	–	2224
2017 Q4	$32K	Buy	+99	New	+$41K	﹤0.01%	2100

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Macquarie Group's EVOK Position: Q1 2018 in Review

Macquarie Group sold out of Evoke Pharma (EVOK) in Q1 2018, closing a stake of 99 shares — an estimated $32K sold.

Macquarie Group first reported a position in EVOK in Q4 2017 and held it in 1 quarter. The position peaked at $32K in Q4 2017. 20 funds tracked by Wall St. Rank hold EVOK as of Q1 2018.

Macquarie Group reported no remaining Evoke Pharma position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 99 Evoke Pharma shares in Q1 2018, an estimated $32K.
Macquarie Group first reported a position in Evoke Pharma in Q4 2017 and held it in 1 quarter.
Macquarie Group's Evoke Pharma position peaked at $32K in Q4 2017.
20 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.